文献速递淋巴瘤

来那度胺联合R-CHOP(R2-CHOP)作为高肿瘤负荷滤泡性淋巴瘤患者一线治疗的单臂、开放标签、2期研究

Lenalidomide in combination with R-CHOP (R2-CHOP) as first-line treatment of patients with high tumour burden follicular lymphoma: a single-arm, open-label, phase 2 study.
PubMed 文献 · Lancet Haematol · 2018-01-01

这项在法国16家医院开展的单臂、开放标签、多中心2期试验,纳入80例既往未经治疗的高肿瘤负荷滤泡性淋巴瘤患者,给予6周期R2-CHOP诱导后利妥昔单抗维持。诱导结束时59例达完全缓解(74%,95%CI 63-83),最常见不良事件为4级中性粒细胞减少(52例,65%)。作者认为该方案安全性可接受并显示抗肿瘤活性,但需未来对照研究证明生存获益。

要点

  • 诱导结束时完全缓解率为74%(95%CI 63-83),30个月时完全缓解率为69%(57-78)。
  • 最常见不良事件为4级中性粒细胞减少,发生于52例(65%)患者。
  • 4例患者在研究期间死亡,均判定与治疗无关。

核心结论

  • 来那度胺联合R-CHOP安全性可接受,在既往未经治疗的高肿瘤负荷滤泡性淋巴瘤患者中显示出抗肿瘤活性。
  • 作者认为,需要未来开展对照研究证明生存获益,该联合方案才可被提议作为滤泡性淋巴瘤的治疗。

研究设计与样本

  • 单臂、开放标签、多中心2期试验,在法国16家淋巴瘤研究协会(LYSA)站点医院开展。
  • 纳入80例既往未经治疗的CD20阳性1、2或3a级滤泡性淋巴瘤患者,年龄18-70岁,符合至少一项GELF高肿瘤负荷标准,ECOG体能状态评分≤2,预期寿命>3个月。

主要发现

  • 2010年12月21日至2012年1月25日入组80例患者,68例(85%)完成6周期R2-CHOP。
  • 诱导结束时59例达完全缓解(74%,95%CI 63-83);入组后30个月时55例达完全缓解(69%,57-78)。
  • 最常见不良事件为4级中性粒细胞减少,发生于52例(65%)患者;最常见非血液学副作用为1-2级感觉神经病变28例(35%)和1-2级一过性皮疹27例(34%)。
  • 研究期间4例患者死亡,均判定与治疗无关。

关键数值与推荐

  • 诱导方案:6周期R2-CHOP每3周一次(每周期第1-5天标准R-CHOP,第1-14天口服来那度胺25 mg/天),随后2次利妥昔单抗输注间隔3周,总疗程24周。
  • 维持治疗:诱导达完全或部分缓解者接受利妥昔单抗每8周一次输注,持续2年。
  • 主要终点:诱导治疗结束时按国际工作组标准化疗效标准达到完全缓解(完全缓解及未确认的完全缓解)的患者比例。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Immunochemotherapy with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) is a standard front-line treatment for follicular lymphoma. The combination of lenalidomide and rituximab has shown high efficacy in relapsed or refractory and untreated follicular lymphoma. We aimed to evaluate the safety and activity of the combination of lenalidomide and R-CHOP (R2-CHOP) in previously untreated patients with high burden follicular lymphoma. METHODS: This single-arm, open-label, multicentre, phase 2 trial was done in 16 hospitals in France, all of which were Lymphoma Study Association (LYSA) sites. Eligible patients were aged 18-70 years and had previously untreated CD20-positive follicular lymphoma of grade 1, 2, or 3a; at least one high tumour burden criterion according to Groupe d'Etude des Lymphomes Folliculaires criteria; an Eastern Cooperative Oncology Group performance status score of 2 or less; and a minimum life expectancy of more than 3 months. Patients received induction therapy with six cycles of R2-CHOP every 3 weeks (one cycle involved standard R-CHOP on days 1-5, and 25 mg oral lenalidomide per day on days 1-14), followed by two rituximab infusions at 3-week intervals. The total treatment schedule was 24 weeks. Patients who achieved a complete or partial response to induction therapy received maintenance therapy consisting of one rituximab infusion every 8 weeks for 2 years. The primary outcome was the proportion of patients who achieved a complete response (complete response and complete response unconfirmed), according to International Workshop to Standardize Response Criteria, at the end of induction treatment. Safety was assessed in all patients who completed treatment. This trial is registered with ClinicalTrials.gov, number NCT01393756, and is closed to accrual. FINDINGS: Between Dec 21, 2010, and Jan 25, 2012, 80 patients were enrolled, and 68 (85%) completed six cycles of R2-CHOP. At the end of the induction phase, 59 patients achieved a complete response (74%, 95% CI 63-83). 55 patients achieved a complete response at 30 months from enrolment (69%, 57-78). The most frequent adverse event was grade 4 neutropenia in 52 (65%) patients. The most frequent non-haematological side-effects included grade 1-2 sensory neuropathy in 28 (35%) patients and grade 1-2 transient rash in 27 (34%) patients. Four patients died during the study period; none of these deaths were judged to be related to treatment. INTERPRETATIONS: Lenalidomide in combination with R-CHOP had an acceptable safety profile and showed anti-cancer activity in patients with previously untreated high burden follicular lymphoma. A future comparative study showing evidence of a survival advantage would be necessary for this combination to be proposed as a treatment for follicular lymphoma. FUNDING: French Ministry of Health, Celgene Corporation, and Amgen France.

来源:Lancet Haematol,查看原文。版权归原作者所有。

引用

  1. Tilly H, Morschhauser F, Casasnovas O, et al. Lenalidomide in combination with R-CHOP (R2-CHOP) as first-line treatment of patients with high tumour burden follicular lymphoma: a single-arm, open-label, phase 2 study. Lancet Haematol. 2018. PMID: 30172345. doi:10.1016/S2352-3026(18)30131-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。